MDT

100.73

-0.34%↓

A

134.59

-3.08%↓

VEEV

221.99

-0.99%↓

HQY

84.34

-2.92%↓

NEOG

9.75

-2.01%↓

MDT

100.73

-0.34%↓

A

134.59

-3.08%↓

VEEV

221.99

-0.99%↓

HQY

84.34

-2.92%↓

NEOG

9.75

-2.01%↓

MDT

100.73

-0.34%↓

A

134.59

-3.08%↓

VEEV

221.99

-0.99%↓

HQY

84.34

-2.92%↓

NEOG

9.75

-2.01%↓

MDT

100.73

-0.34%↓

A

134.59

-3.08%↓

VEEV

221.99

-0.99%↓

HQY

84.34

-2.92%↓

NEOG

9.75

-2.01%↓

MDT

100.73

-0.34%↓

A

134.59

-3.08%↓

VEEV

221.99

-0.99%↓

HQY

84.34

-2.92%↓

NEOG

9.75

-2.01%↓

Search

Cytek Biosciences Inc

Aperta

SettoreSettore sanitario

5.28 -5.04

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

5.26

Massimo

5.57

Metriche Chiave

By Trading Economics

Entrata

105K

-5.5M

Vendite

6.7M

52M

EPS

-0

Margine di Profitto

-10.476

Dipendenti

692

EBITDA

6.4M

-4.2M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+11.78% upside

Dividendi

By Dow Jones

Utili prossimi

26 feb 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

189M

690M

Apertura precedente

10.32

Chiusura precedente

5.28

Notizie sul Sentiment di mercato

By Acuity

17%

83%

30 / 360 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

Cytek Biosciences Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

22 gen 2026, 21:55 UTC

Utili

Capital One Financial Posts Higher 4Q Profit As Lending Increases

22 gen 2026, 23:52 UTC

Utili

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- Update

22 gen 2026, 23:48 UTC

Discorsi di Mercato

Nikkei May Rise as Tensions Between U.S. and Europe Ease -- Market Talk

22 gen 2026, 23:42 UTC

Discorsi di Mercato

Gold Edges Lower on Possible Profit-Taking -- Market Talk

22 gen 2026, 23:40 UTC

Discorsi di Mercato

Spark NZ's Market Share Loss Concerns Bear -- Market Talk

22 gen 2026, 23:30 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

22 gen 2026, 23:30 UTC

Discorsi di Mercato

Genesis Energy Can Beat Newly Upgraded Earnings Goal -- Market Talk

22 gen 2026, 22:37 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Capital One CEO: Brex Buy Reflects Business Payments Focus -- Market Talk

22 gen 2026, 21:59 UTC

Acquisizioni, Fusioni, Takeovers

Capital One Strikes $5.15 Billion Deal for Fintech Brex -- Update

22 gen 2026, 21:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Tech, Media & Telecom Roundup: Market Talk

22 gen 2026, 21:44 UTC

Utili

Self-Driving Stock Mobileye Plunged After Earnings. Here's Why. -- Barrons.com

22 gen 2026, 21:32 UTC

Acquisizioni, Fusioni, Takeovers

Capital One: Brex Invented Integrated Combination of Corporate Credit Cards, Spend Management Software and Banking in Single Platform >COF

22 gen 2026, 21:31 UTC

Acquisizioni, Fusioni, Takeovers

Capital One: Brex Is a Modern, AI-native Software Platform Offering Intelligent Finance Solutions >COF

22 gen 2026, 21:31 UTC

Acquisizioni, Fusioni, Takeovers

Capital One: Franceschi Will Continue to Lead Brex as Part of Capital One >COF

22 gen 2026, 21:30 UTC

Acquisizioni, Fusioni, Takeovers

Capital One to Acquire Brex in Combination of Stk and Cash Transaction Valued at $5.15 B >COF

22 gen 2026, 21:30 UTC

Utili

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results -- WSJ

22 gen 2026, 21:30 UTC

Acquisizioni, Fusioni, Takeovers

Capital One To Acquire Brex >COF

22 gen 2026, 21:13 UTC

Utili

Intel Returns to Losses in Q4 as It Ramps Up Spending on Chip Production -- WSJ

22 gen 2026, 21:11 UTC

Utili

Intuitive Surgical Sees 2026 Impact From Tariffs 1.2% of Revenue, Plus or Minus 10 Basis Points >ISRG

22 gen 2026, 21:11 UTC

Utili

Intuitive Surgical Sees 2026 Adjusted Gross Profit Margin 67%-68% >ISRG

22 gen 2026, 21:10 UTC

Utili

Intuitive Surgical Sees 2026 Worldwide Da Vinci Procedure Growth of 13%-15% >ISRG

22 gen 2026, 21:06 UTC

Utili

Capital One 4Q Total Non-Interest Expense Increased 13% to $9.3B >COF

22 gen 2026, 21:05 UTC

Utili

Capital One 4Q Provision for Credit Losses Increased $4.1B >COF

22 gen 2026, 21:05 UTC

Utili

Capital One 4Q Rev $15.58B >COF

22 gen 2026, 21:05 UTC

Utili

Capital One 4Q EPS $3.26 >COF

22 gen 2026, 21:05 UTC

Utili

Capital One 4Q Net Interest Margin 8.26% >COF

22 gen 2026, 21:05 UTC

Utili

Capital One 4Q Net $2.13B >COF

22 gen 2026, 21:05 UTC

Utili

Capital One 4Q Adj EPS $3.86 >COF

22 gen 2026, 21:05 UTC

Utili

Capital One 4Q Net Charge-Offs $3.8B >COF

22 gen 2026, 21:05 UTC

Utili

Intuitive Surgical 4Q EPS $2.21 >ISRG

Confronto tra pari

Modifica del prezzo

Cytek Biosciences Inc Previsione

Obiettivo di Prezzo

By TipRanks

11.78% in crescita

Previsioni per 12 mesi

Media 6.17 USD  11.78%

Alto 7.5 USD

Basso 5 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Cytek Biosciences Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

3 ratings

1

Acquista

2

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

3.7 / 3.8Supporto e resistenza

A breve termine

Weak Bullish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

30 / 360 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
help-icon Live chat